| Outcome Measures: |
Primary: Mean Change in Hemoglobin From Baseline and Over the Evaluation Period (Mean Over Week 24 and 28), Blood samples were collected at given time points from participants for hemoglobin measurements. Evaluation period hemoglobin value was defined as the mean of all available post-randomization hemoglobin values (on and off-treatment) during the evaluation period (Week 24 to Week 28 inclusive). For the primary analysis, the missing post-Baseline hemoglobin values were imputed using pre-specified multiple imputations. Change from Baseline was defined as the average of post-randomization values during the evaluation period minus Baseline value. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using the Analysis of Covariance (ANCOVA) model with terms for treatment, Baseline hemoglobin, and region., Baseline (Day 1) and Week 24 to Week 28 | Secondary: Percentage of Participants With Hemoglobin Increase of >=1.0 Grams Per Deciliter From Baseline to Evaluation Period, Blood samples were collected at given time points for hemoglobin measurements. Evaluation period hemoglobin value was defined as the mean of all available post-randomization hemoglobin values (on and off-treatment) during the evaluation period (Week 24 to Week 28 inclusive). For the primary analysis, the missing post-Baseline hemoglobin values were imputed using pre-specified multiple imputations. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date. Percentage of participants with hemoglobin increase of \>=1.0 grams per deciliter from Baseline to evaluation period was analyzed using Cochran-Mantel-Haenszel (CMH) chi-squared test. The percentage values presented has been rounded off., Baseline (Day 1) and Week 24 to Week 28|Change From Baseline in Short Form-36 (SF-36) Questionnaire Vitality Domain Score by Traditional Scoring at Week 28, The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the 8 health domains: Physical Functioning, Role-Physical (role limitations caused by physical problems), Social Functioning, Bodily Pain, Mental Health, Role-Emotional (role limitations caused by emotional problems), Vitality, and General Perception of Health.Each domain is scored from 0 (poorer health) to 100 (better health). Vitality domain score ranges from 0-100; higher score indicates a better health state \& better functioning. Change from Baseline was calculated as Post-Dose Visit Value at Week 28 minus Baseline. For primary analysis, the missing on-treatment Week 28 SF-36 Vitality domain scores were imputed using pre-specified multiple imputations. Baseline value was latest non-missing pre-dose assessment on or before randomization date. Analysis was performed using ANCOVA model with terms for treatment, Baseline score, and region., Baseline (Day 1) and Week 28|Percentage of Participants With Hgb Response (Hgb in the 11-12 Grams/Deciliter Range) During Evaluation Period (Week 24 to Week 28 Inclusive), Mean hemoglobin during the evaluation period was defined as the mean of all evaluable hemoglobin values during the evaluation period (Week 24 to Week 28 inclusive) including any evaluable unscheduled hemoglobin values that were taken during this period. Percentage of participants with Hgb response was defined as participants with mean Hgb within range (11-12 grams per deciliter during the evaluation period (Week 24 to Week 28 inclusive) and it was analyzed using Cochran-Mantel-Haenszel (CMH) chi-squared test. The percentage values presented has been rounded off., Week 24 to Week 28|Percentage of Time With Hgb Within the Target Range (11-12 Grams Per Deciliter) During Evaluation Period (Week 24 to Week 28 Inclusive) (Hodges-Lehmann Estimate), Percentage of days for which participant's Hgb was within the target range of 11-12 grams per deciliter during the evaluation period (Week 24 to Week 28 inclusive), including any unscheduled evaluable Hgb values that were taken during this time period. Percentage of time for which Hgb was within the target range (11-12 grams per deciliter) for a participant was calculated by dividing 'the total number of days that Hgb was within range during Week 24 to 28' by 'the total number of days the participant remained on treatment during Week 24 to 28'., Week 24 to Week 28|Percentage of Time With Hgb Within the Target Range (11-12 Grams Per Deciliter) During Evaluation Period (Week 24 to Week 28 Inclusive) (Mann-Whitney Estimate), Percentage of days for which participant's Hgb was within the target range of 11-12 grams per deciliter during the evaluation period (Week 24 to Week 28 inclusive), including any unscheduled evaluable Hgb values that were taken during this time period. Percentage of time for which Hgb was within the target range (11-12 grams per deciliter) for a participant was calculated by dividing 'the total number of days that Hgb was within range during Week 24 to 28' by 'the total number of days the participant remained on treatment during Week 24 to 28', Week 24 to Week 28|Change From Baseline in Post-randomization Hgb at Week 28, Blood samples were collected at given time points for hemoglobin measurements. Change from Baseline in Hgb was analyzed using a mixed model repeated measures (MMRM) approach. Change from Baseline was calculated as Post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date., Baseline (Day 1) and Week 28|Rate of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria, The incidence rate of participants permanently stopping randomized treatment due to meeting rescue criteria is presented., Up to Week 28|Change From Baseline by Domain and Single Item Scores on the Chronic Kidney Disease -Anemia Questionnaire (CKD-AQ) Symptom Questionnaire, CKD-AQ is 21-item patient reported outcomes measure assessing symptoms \& symptom impact in participants with anemia associated with CKD.CKD-AQ identified 3 domains:1.Tired/Low Energy/Weak scale consisting of ten items;2.Chest Pain/Shortness of Breath scale consisting of four items and 3.Cognitive scale consisting of three items;Single items included: 4.Difficulty Sleeping;5.Difficulty Standing for long periods of time;6.Severity-Shortness of breath while sitting/resting;7.Time with Shortness of breath while not doing activity.Single-item measures were recorded based on 0-100 scoring with 0 is worst possible \& 100 is best possible score.Total domain score is calculated as average of items in each domain \& ranged from 0-100 where 0 is worst possible and 100 is best possible score.Change from Baseline was calculated as post-dose visit value minus Baseline.Baseline was latest non-missing pre-dose assessment on or before randomization date. Adjusted mean \& standard error is presented., Baseline (Day 1) and Week 28|Change From Baseline in Patient Global Impression of Severity (PGI-S), The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated worse outcome. Change from Baseline was calculated as Post-Dose visit value minus Baseline value. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date. Adjusted mean and standard error is presented., Baseline (Day 1) and Week 28|Change From Baseline in the SF-36 Physical Functioning Domain, The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following eight health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality, and general perception of health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning domain score ranges from 0-100; higher score indicates a better health state and better functioning. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date., Baseline (Day 1) and Week 28|Change From Baseline of the SF-36 Individual Items in the Vitality Domain, The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following eight health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality, and general perception of health. Individual vitality items include: 1. Did you feel full of life?, 2. Did you have a lot of energy?, 3. Did you feel worn out?, 4. Did you feel tired?. Score of each item in the vitality domain ranges from 0-100; higher score indicates better health state and better functioning. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date., Baseline (Day 1) and Week 28|Number of Participants Currently Employed as Per Work Productivity and Activity Impairment Questionnaire: Anemic Symptoms Clinical Practice Version (WPAI-ANS-CPV), WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities. It contains 2 concepts-work productivity impairment measured via absenteeism(time missed from work), presenteeism(impairment at work) and regular daily activity impairment. WPAI questions (Q) were:1) currently employed,2) work time missed due to problem, 3) impairment while working due to problem, 4) overall work impairment due to problem, 5) activity impairment due to problem. WPAI generates 4 domain scores:percent (%) of work time missed(absenteeism),% of impairment while working(presenteeism),% of overall work impairment(absenteeism and presenteeism combined),% of activity impairment. Number of participants currently employed as per WPAI-ANS-CPV is presented., Week 8, Week 12 and Week 28|Change From Baseline in WPAI-ANS-CPV: Percent Time Missed From Work, WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities. It contains 2 concepts-work productivity impairment measured via absenteeism (time missed from work), presenteeism (impairment at work) and regular daily activity impairment. WPAI questions (Q) were: 1) currently employed, 2) work time missed due to problem, 3) impairment while working due to problem, 4)overall work impairment due to problem, 5) activity impairment due to problem. Percent work time missed due to problem was a subscale and calculated as: Q2/(Q2+Q4) for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date., Baseline (Day 1), Week 8, Week 12 and Week 28|Change From Baseline in WPAI-ANS-CPV: Mean Hours Missed From Work in the Past 7 Days, WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities. It contains 2 concepts-work productivity impairment measured via absenteeism (time missed from work), presenteeism (impairment at work) and regular daily activity impairment. WPAI Qs were: 1) currently employed, 2) work time missed due to problem, 3) impairment while working due to problem, 4) overall work impairment due to problem, 5) activity impairment due to problem. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date., Baseline (Day 1), Week 8, Week 12 and Week 28|Change From Baseline in WPAI: Percent Impairment at Work, WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities.It contains 2 concepts-work productivity impairment measured via absenteeism(time missed from work),presenteeism(impairment at work) and regular daily activity impairment.WPAI Qs were:1)currently employed,2)work time missed due to problem,3)impairment while working due to problem,4)overall work impairment due to problem,5)activity impairment due to problem. % Impairment while Working due to Problem was subscale and calculated as: Q5/10 for those who were currently employed and actually worked in past 7 days. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment and less productivity. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before randomization date., Baseline (Day 1), Week 8, Week 12 and Week 28|Change From Baseline in WPAI: Percent Overall Work Impairment, WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities. It contains 2 concepts-work productivity impairment measured via absenteeism (time missed from work), presenteeism (impairment at work) and regular daily activity impairment. WPAI Qs were: 1) currently employed, 2) work time missed due to problem, 3) impairment while working due to problem, 4) overall work impairment due to problem, 5) activity impairment due to problem. Percent overall work impairment due to problem was a subscale and calculated as: Q2/(Q2+Q4)+\[(1-Q2/(Q2+Q4))×(Q5/10)\] for those who were currently employed. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before randomization date., Baseline (Day 1), Week 8, Week 12 and Week 28|Change From Baseline in WPAI: Percent Regular Daily Activity Impairment, WPAI-ANS-CPV is anemia specific questionnaire designed as self-reported quantitative assessment of social functioning related to work and regular daily activities.It contains 2 concepts-work productivity impairment measured via absenteeism (time missed from work), presenteeism (impairment at work) and regular daily activity impairment. WPAI Qs were: 1) currently employed, 2) work time missed due to problem, 3) impairment while working due to problem, 4) overall work impairment due to problem, 5) activity impairment due to problem. Percent activity impairment due to problem was a subscale and calculated as: Q5/10 for all respondents. Subscale score was expressed as an impairment percentage (range: 0-100%) where higher numbers indicate greater impairment. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before randomization date., Baseline (Day 1), Week 8, Week 12 and Week 28|Change From Baseline in EuroQol 5 Dimension 5 Level Health Utility Index (EQ-5D-5L) Utility Score, The EQ-5D-5L is a self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by a 5-point Likert scale (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, and 5: extreme problems). The responses for the five dimension together form a five-figure description of health state. Each of these five-figure health states have attached valuation (utility score), expressed as single index on a scale from 0-1, where 1 is full health and 0 is worst health. The higher the score the better the health status. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date., Baseline (Day 1) and Week 28|Change From Baseline in EuroQol Visual Analogue Scale (EQ-VAS) Score, The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'the best health you can imagine' and 'the worst health you can imagine' at the time of completion. It is a self-assessment visual analogue scale, ranging from 0=worst imaginable to 100=best. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date., Baseline (Day 1) and Week 28|Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Pressure (MAP) at Week 28, SBP, DBP and MAP were measured with participants in a seated position after at least a 5-minute of rest. MAP is the average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as post-dose visit value minus Baseline. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date., Baseline (Day 1) and Week 28|Percentage of Participants With at Least One Blood Pressure (BP) Exacerbation Event, Percentage of participants with at least one BP event is presented. BP exacerbation is defined as: SBP exacerbation: SBP \>= 25 mmHg increase from Baseline or SBP \>= 180 mmHg; DBP exacerbation: DBP \>= 15 mmHg increase from Baseline or DBP \>= 110 mmHg. Percentage of participants with at least one BP event is presented. The percentage values presented has been rounded off., Up to Week 28
|
| Locations: |
GSK Investigational Site, Homewood, Alabama, 35209, United States|GSK Investigational Site, Little Rock, Arkansas, 72204, United States|GSK Investigational Site, Downey, California, 90242, United States|GSK Investigational Site, Fresno, California, 93720, United States|GSK Investigational Site, Lynwood, California, 90262, United States|GSK Investigational Site, Northridge, California, 91324, United States|GSK Investigational Site, Northridge, California, 91325, United States|GSK Investigational Site, Riverside, California, 82503, United States|GSK Investigational Site, Salinas, California, 93901, United States|GSK Investigational Site, Santa Ana, California, 92704, United States|GSK Investigational Site, Denver, Colorado, 80230, United States|GSK Investigational Site, Hartford, Connecticut, 06112, United States|GSK Investigational Site, Middlebury, Connecticut, 06762, United States|GSK Investigational Site, Coral Springs, Florida, 33067, United States|GSK Investigational Site, Hollywood, Florida, 33024, United States|GSK Investigational Site, Kissimmee, Florida, 34741, United States|GSK Investigational Site, Lauderdale Lakes, Florida, 33313, United States|GSK Investigational Site, Pembroke Pines, Florida, 33028, United States|GSK Investigational Site, Tampa, Florida, 33614, United States|GSK Investigational Site, Adairsville, Georgia, 30103, United States|GSK Investigational Site, Macon, Georgia, 31201, United States|GSK Investigational Site, Macon, Georgia, 31217, United States|GSK Investigational Site, Statesboro, Georgia, 30458, United States|GSK Investigational Site, Indianapolis, Indiana, 46260, United States|GSK Investigational Site, Overland Park, Kansas, 66210, United States|GSK Investigational Site, Buckley, Michigan, 49620, United States|GSK Investigational Site, Detroit, Michigan, 48202, United States|GSK Investigational Site, Saint Clair Shores, Michigan, 48081, United States|GSK Investigational Site, Brookhaven, Mississippi, 39601, United States|GSK Investigational Site, Saint Louis, Missouri, 63136, United States|GSK Investigational Site, Rochester, New Hampshire, 03867, United States|GSK Investigational Site, Asheville, North Carolina, 28801, United States|GSK Investigational Site, Charlotte, North Carolina, 28262, United States|GSK Investigational Site, Durham, North Carolina, 27704, United States|GSK Investigational Site, Midwest City, Oklahoma, 73130, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73112, United States|GSK Investigational Site, Beaver, Pennsylvania, 15009, United States|GSK Investigational Site, Duncansville, Pennsylvania, 16635, United States|GSK Investigational Site, Scottdale, Pennsylvania, 15683, United States|GSK Investigational Site, Smithfield, Pennsylvania, 15478, United States|GSK Investigational Site, West Reading, Pennsylvania, 19611, United States|GSK Investigational Site, Orangeburg, South Carolina, 29118, United States|GSK Investigational Site, Kingsport, Tennessee, 37660, United States|GSK Investigational Site, Memphis, Tennessee, 38163, United States|GSK Investigational Site, DeSoto, Texas, 75115, United States|GSK Investigational Site, El Paso, Texas, 79935, United States|GSK Investigational Site, McAllen, Texas, 78503, United States|GSK Investigational Site, Waxahachie, Texas, 75165, United States|GSK Investigational Site, Norfolk, Virginia, 23502, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1128AAF, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425AGC, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, 7600, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, B7600FZN, Argentina|GSK Investigational Site, San Nicolas, Buenos Aires, B2900DMH, Argentina|GSK Investigational Site, Cordoba, Córdova, 5003, Argentina|GSK Investigational Site, Rosario, Santa Fe, S2000DEJ, Argentina|GSK Investigational Site, Santa Fe, 3000, Argentina|GSK Investigational Site, Sydney, New South Wales, 2010, Australia|GSK Investigational Site, Heidelberg, Victoria, 3084, Australia|GSK Investigational Site, Parkville, Victoria, 3050, Australia|GSK Investigational Site, Murdoch, Western Australia, 6150, Australia|GSK Investigational Site, Fitzroy, 3065, Australia|GSK Investigational Site, Feira de Santana., Bahia, 44001-584, Brazil|GSK Investigational Site, Salvador, Bahia, 40415-065, Brazil|GSK Investigational Site, Vitoria, Espírito Santo, 29055450, Brazil|GSK Investigational Site, Ribeirão Preto, São Paulo, 14025170, Brazil|GSK Investigational Site, Santo André - SP, São Paulo, 09080-110, Brazil|GSK Investigational Site, Sao Jose do Rio Preto, São Paulo, 15015200, Brazil|GSK Investigational Site, Sao Jose do Rio Preto, São Paulo, 15090-000, Brazil|GSK Investigational Site, São Bernardo do Campo, São Paulo, 09715090, Brazil|GSK Investigational Site, São Paulo, 04038002, Brazil|GSK Investigational Site, Victoria, British Columbia, V8V 4A1, Canada|GSK Investigational Site, Brampton, Ontario, L6T 0G1, Canada|GSK Investigational Site, Guelph, Ontario, N1H 1B1, Canada|GSK Investigational Site, Kitchener, Ontario, N2H 5Z8, Canada|GSK Investigational Site, Ottawa, Ontario, K1H 1A2, Canada|GSK Investigational Site, Sarnia, Ontario, N7T 4X3, Canada|GSK Investigational Site, Sudbury, Ontario, P3A-1W8, Canada|GSK Investigational Site, Toronto, Ontario, M5B 1W8, Canada|GSK Investigational Site, Toronto, Ontario, M9N 1N8, Canada|GSK Investigational Site, Toronto, Ontario, M9V 4B4, Canada|GSK Investigational Site, Montréal, Quebec, H1M 1B1, Canada|GSK Investigational Site, Quebec city, Quebec, G2J 0C4, Canada|GSK Investigational Site, St-Charles-Borromée, Quebec, J6E 2B4, Canada|GSK Investigational Site, Quebec, G3K 2P8, Canada|GSK Investigational Site, Grenoble cedex 9, 38043, France|GSK Investigational Site, Le Mans cedex 9, 72037, France|GSK Investigational Site, Marseille cedex 5, 13385, France|GSK Investigational Site, Melun, 77000, France|GSK Investigational Site, Mulhouse cedex, 68070, France|GSK Investigational Site, Nantes Cedex 1, 44093, France|GSK Investigational Site, Nice Cedex 1, 06001, France|GSK Investigational Site, Saint-Priest en Jarez, 42270, France|GSK Investigational Site, Catanzaro, Calabria, 88100, Italy|GSK Investigational Site, Napoli, Campania, 80131, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, 40138, Italy|GSK Investigational Site, Modena, Emilia-Romagna, 41124, Italy|GSK Investigational Site, Genova, Liguria, 16132, Italy|GSK Investigational Site, Pavia, Lombardia, 27100, Italy|GSK Investigational Site, Mestre, Veneto, 30174, Italy|GSK Investigational Site, Busan, 49201, Korea, Republic of|GSK Investigational Site, Busan, 49241, Korea, Republic of|GSK Investigational Site, Daegu-si, 42601, Korea, Republic of|GSK Investigational Site, Daegu, 42415, Korea, Republic of|GSK Investigational Site, Gyeonggi-do, 463-712, Korea, Republic of|GSK Investigational Site, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|GSK Investigational Site, Seoul, 03312, Korea, Republic of|GSK Investigational Site, Seoul, 08308, Korea, Republic of|GSK Investigational Site, Leon, Guanajuato, 37530, Mexico|GSK Investigational Site, Guadalajara, Jalisco, 44150, Mexico|GSK Investigational Site, Monterrey, Nuevo León, 64060, Mexico|GSK Investigational Site, Boca del Rio, Veracruz, 24290, Mexico|GSK Investigational Site, Córdoba, Veracruz, 94550, Mexico|GSK Investigational Site, Merida, Yucatán, 97070, Mexico|GSK Investigational Site, Guadalajara, 44600, Mexico|GSK Investigational Site, Merida, 97000, Mexico|GSK Investigational Site, Veracruz, 91900, Mexico|GSK Investigational Site, Bialystok, 15-276, Poland|GSK Investigational Site, Ciechanow, 06-400, Poland|GSK Investigational Site, Krakow, 30510, Poland|GSK Investigational Site, Krakow, 31-513, Poland|GSK Investigational Site, Krakow, 31-559, Poland|GSK Investigational Site, Lodz, 92-213, Poland|GSK Investigational Site, Lublin, 20-064, Poland|GSK Investigational Site, Olawa, 55-200, Poland|GSK Investigational Site, Pleszew, 63-300, Poland|GSK Investigational Site, Sosnowiec, 41-200, Poland|GSK Investigational Site, Swidnik, 21-040, Poland|GSK Investigational Site, Szczecin, 70-111, Poland|GSK Investigational Site, Tczew, 83-110, Poland|GSK Investigational Site, Warszawa, 01-868, Poland|GSK Investigational Site, Warszawa, 02-801, Poland|GSK Investigational Site, Warszawa, 04-749, Poland|GSK Investigational Site, Brasov, 500283, Romania|GSK Investigational Site, Bucharest, 022328, Romania|GSK Investigational Site, Bucharest, 042122, Romania|GSK Investigational Site, Cluj-Napoca, 400139, Romania|GSK Investigational Site, Craiova, 200642, Romania|GSK Investigational Site, Deva, 330084, Romania|GSK Investigational Site, Oradea, 410469, Romania|GSK Investigational Site, Targu Mures, 540096, Romania|GSK Investigational Site, Timisoara, 300723, Romania|GSK Investigational Site, Izhevsk, 426061, Russian Federation|GSK Investigational Site, Kaliningrad, 236016, Russian Federation|GSK Investigational Site, Kemerovo, 650066, Russian Federation|GSK Investigational Site, Krasnoyarsk, 660022, Russian Federation|GSK Investigational Site, Moscow, 121359, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, 603126, Russian Federation|GSK Investigational Site, Pyatigorsk, 357500, Russian Federation|GSK Investigational Site, Pyatigorsk, 357538, Russian Federation|GSK Investigational Site, Rostov-on-Don, 344022, Russian Federation|GSK Investigational Site, Ryazan, 390037, Russian Federation|GSK Investigational Site, Saint Petersburg, 194355, Russian Federation|GSK Investigational Site, Saint Petersburg, 197022, Russian Federation|GSK Investigational Site, Stavropol, 355017, Russian Federation|GSK Investigational Site, Yaroslavl, 150000, Russian Federation|GSK Investigational Site, Yaroslavl, 150030, Russian Federation|GSK Investigational Site, Yaroslavl, 150062, Russian Federation|GSK Investigational Site, Badalona, 08916, Spain|GSK Investigational Site, Madrid, 28040, Spain|GSK Investigational Site, Santiago de Compostela, 15890, Spain|GSK Investigational Site, Canterbury, Kent, CT1 3NG, United Kingdom|GSK Investigational Site, Derby, DE22 3NE, United Kingdom|GSK Investigational Site, London, SE5 9RS, United Kingdom|GSK Investigational Site, Peterborough, PE3 9GZ, United Kingdom|GSK Investigational Site, Plymouth, PL6 8DH, United Kingdom|GSK Investigational Site, Shrewsbury, SY3 8XQ, United Kingdom|GSK Investigational Site, Swansea, SA6 6NL, United Kingdom
|
